6-[(2-Methylpropan-2-yl)oxycarbonylamino]imidazo[1,2-a]pyridine-2-carboxylic acid | 1227962-41-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-[(2-Methylpropan-2-yl)oxycarbonylamino]imidazo[1,2-a]pyridine-2-carboxylic acid
• CAS: 1227962-41-5
• 化学式: C₁₃H₁₅N₃O₄
• 分子量: 277.28
• InChiKey: FENJOWYMTGQEFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-[(2-Methylpropan-2-yl)oxycarbonylamino]imidazo[1,2-a]pyridine-2-carboxylic acid 在 盐酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 1,4-二氧六环 为溶剂， 生成
  参考文献：
  名称：

  [EN] SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE
  [FR] COMPOSÉS DE SECO-CYCLOPROPAPYRROLOINDOLE, CONJUGUÉS ANTICORPS-MÉDICAMENT DE CEUX-CI, ET PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  公式（I）中的seco-Cyclopropapyrroloindole化合物，其中Hal、R1、R2和R3如申请中定义，是强效的抗癌药物，可以用于抗体药物偶联物。

  公开号：

  WO2018035391A1
• 作为产物：
  描述：

  6-硝基咪唑[1,2-Alpha]吡啶-2-羧酸乙酯 在 palladium on activated charcoal 、 氢气 、 sodium hydroxide 作用下， 生成 6-[(2-Methylpropan-2-yl)oxycarbonylamino]imidazo[1,2-a]pyridine-2-carboxylic acid
  参考文献：
  名称：

  [EN] SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE
  [FR] COMPOSÉS DE SECO-CYCLOPROPAPYRROLOINDOLE, CONJUGUÉS ANTICORPS-MÉDICAMENT DE CEUX-CI, ET PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  公式（I）中的seco-Cyclopropapyrroloindole化合物，其中Hal、R1、R2和R3如申请中定义，是强效的抗癌药物，可以用于抗体药物偶联物。

  公开号：

  WO2018035391A1

文献信息

• [EN] CC-1065 ANALOGS AND THEIR CONJUGATES<br/>[FR] NOUVEAUX ANALOGUES DE CC-1065 ET LEURS CONJUGUÉS
  申请人：SYNTARGA BV

  公开号：WO2010062171A3

  公开（公告）日：2013-03-14
• CC-1065 ANALOGS AND THEIR CONJUGATES
  申请人：Syntarga B.V.

  公开号：EP2344478B1

  公开（公告）日：2017-09-27
• Novel cc-1065 Analogs and Their Conjugates
  申请人：Beusker Patrick Henry

  公开号：US20110207767A1

  公开（公告）日：2011-08-25

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
• US9815784B2
  申请人：——

  公开号：US9815784B2

  公开（公告）日：2017-11-14
• [EN] NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES<br/>[FR] NOUVEAUX ANALOGUES DE CC-1065 ET LEURS CONJUGUÉS
  申请人：SYNTARGA BV

  公开号：WO2010062171A2

  公开（公告）日：2010-06-03

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.